Although large cardiovascular outcome trials have consistently shown that GLP-1 RAs, particularly semaglutide and liraglutide, reduce all-cause death in people with type 2 diabetes [9, 10], these studies did not formally stratify death outcomes by age group, limiting direct comparisons with our findings. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.